Camrelizumab Plus Apatinib
FAD-HCC-001
Phase 2 small_molecule active
Quick answer
Camrelizumab Plus Apatinib for Unresectable Hepatocellular Carcinoma (HCC) is a Phase 2 program (small_molecule) at Nanjing Zenshine Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Nanjing Zenshine Pharmaceuticals
- Indication
- Unresectable Hepatocellular Carcinoma (HCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active